161 related articles for article (PubMed ID: 17638731)
1. Efalizumab in the treatment of discoid lupus erythematosus.
Usmani N; Goodfield M
Arch Dermatol; 2007 Jul; 143(7):873-7. PubMed ID: 17638731
[TBL] [Abstract][Full Text] [Related]
2. [Successful therapy of discoid lupus erythematosus with efalizumab].
Booken N; Schumann T; Fuchslocher M; Goerdt S; Goebeler M
Hautarzt; 2010 Mar; 61(3):246-9. PubMed ID: 19436973
[TBL] [Abstract][Full Text] [Related]
3. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus.
Winchester D; Duffin KC; Hansen C
Lupus; 2012 Aug; 21(9):1007-10. PubMed ID: 22438028
[TBL] [Abstract][Full Text] [Related]
4. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
5. Refractory discoid lupus erythematosus: response to efalizumab.
Rodríguez-Lojo R; Paradela S; Martínez-Gómez W; Fernández-Torres R; Fonseca E
J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1203-5. PubMed ID: 19220642
[No Abstract] [Full Text] [Related]
6. Efalizumab-associated papular psoriasis.
Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases].
Delaporte E; Catteau B; Sabbagh N; Gosselin P; Breuillard F; Doutre MS; Broly F; Piette F; Bergoend H
Ann Dermatol Venereol; 1997; 124(2):151-6. PubMed ID: 9740825
[TBL] [Abstract][Full Text] [Related]
8. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
De Souza A; Strober BE; Merola JF; Oliver S; Franks AG
J Drugs Dermatol; 2012 Oct; 11(10):1224-6. PubMed ID: 23134988
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
10. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
[TBL] [Abstract][Full Text] [Related]
11. Control of widespread hypertrophic lupus erythematosus with T-cell-directed biologic efalizumab.
Navarini AA; Kerl K; French LE; Trüeb RM
Dermatology; 2010; 220(3):249-53. PubMed ID: 20110637
[TBL] [Abstract][Full Text] [Related]
12. Efalizumab for severe atopic dermatitis: a pilot study in adults.
Takiguchi R; Tofte S; Simpson B; Harper E; Blauvelt A; Hanifin J; Simpson E
J Am Acad Dermatol; 2007 Feb; 56(2):222-7. PubMed ID: 17097386
[TBL] [Abstract][Full Text] [Related]
13. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
14. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
15. Is chronic cutaneous discoid lupus protective against severe renal disease in patients with systemic lupus erythematosus?
Merola JF; Chang CA; Sanchez MR; Prystowsky SD
J Drugs Dermatol; 2011 Dec; 10(12):1413-20. PubMed ID: 22134565
[TBL] [Abstract][Full Text] [Related]
16. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus.
Tlacuilo-Parra A; Guevara-Gutiérrez E; Gutiérrez-Murillo F; Soto-Ortiz A; Barba-Gómez F; Hernández-Torres M; Salazar-Páramo M
Rheumatology (Oxford); 2005 Dec; 44(12):1564-8. PubMed ID: 16159951
[TBL] [Abstract][Full Text] [Related]
17. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
[TBL] [Abstract][Full Text] [Related]
19. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
[TBL] [Abstract][Full Text] [Related]
20. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
Papp KA; Toth D; Rosoph L
BMC Dermatol; 2006 Oct; 6():9. PubMed ID: 17067371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
